Join Bell Financial Group's Senior Market Analyst Grady Wulff as she sat down with Dr. Liz Dallimore, CEO & MD of Argenica Therapeutics (ASX:AGN) to discuss the company's lead drug candidate ARG-007, and its pathway to commercialisation to become the world's first neuroprotective drug for the protection of brain cells post stroke or catastrophic brain injury. In this interview, Liz covers:• (0:40) an overview of Argenica Therapeutics (ASX:AGN) • (1:28) details on ARG-007, including its mechanism in protecting brain cells after stroke• (4:59) expected runway, and potential need for additional financing pre-Phase 3• (8:42) other drug candidates in development within Argenica’s pipeline• (10:01) expected investor news flow over the next 12 monthsNote: This interview was filmed on 24 September 2025.

Ver todos los episodios